NICE delays Alzheimer’s decision

The National Institute for Health and Clinical Excellence (NICE) has requested more evidence from pharmaceutical companies before committing itself to a final decision on the future of four major Alzheimer’s drugs.Draft proposals to end the routine prescription of four major drugs for newly diagnosed Alzheimer’s patients received an unprecedented level of public and professional response…